- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids
- Drug · Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 5 Years to 9 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Interventions
- Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Prednisone, Topical mometasone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Autoimmune Hepatitis
- Interventions
- zetomipzomib, placebo, zetomipzomib in open-label extension
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
- Conditions
- Allergic Reaction (IgA) Vasculitis
- Interventions
- BBD-1 Multi target Immune Enhancement Targeting Agent
- Drug
- Lead sponsor
- Qifeng Zhang
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the Hip
- Interventions
- Prednisone, Dexamethasone, Placebo
- Drug
- Lead sponsor
- WellSpan Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- York, Pennsylvania
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Interventions
- Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lupus Nephritis
- Interventions
- zetomipzomib, placebo
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more
- Conditions
- Lupus Nephritis
- Interventions
- Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Covina, California • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
- Interventions
- Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Congenital Heart Disease, Disorder of Fetus or Newborn
- Interventions
- methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Osteoarthritis of Facet Joint of Lumbar Spine
- Interventions
- Adipose-derived stem cell injection, Corticosteroid injection
- Device · Drug
- Lead sponsor
- InGeneron, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Deerfield Beach, Florida • Sioux Falls, South Dakota
- Conditions
- Myositis Associated Interstitial Lund Disease (MA-ILD)
- Interventions
- Nintedanib, Placebo, Standard of Care
- Drug
- Lead sponsor
- Rohit Aggarwal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more
- Conditions
- Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
- Interventions
- Hydrocortisone (Solucortef), Insulin pump (Medtronic)
- Drug · Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Nipocalimab, Standard-of-care treatment
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Los Alamitos, California • Rancho Mirage, California • Santa Ana, California + 18 more
- Conditions
- Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
- Interventions
- Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]
- Procedure · Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Acromioclavicular Sprain
- Interventions
- Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection
- Drug
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Tacoma, Washington
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Exicorilant, Enzalutamide, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
- Interventions
- Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- prednisone, methylprednisolone, questionnaire administration
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Current standard of care treatment options
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 26
- States / cities
- La Jolla, California • La Palma, California • Los Angeles, California + 22 more
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Interventions
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more